Linked Life Data

10955874

Source:http://linkedlifedata.com/resource/pubmed/id/10955874

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-9-21
pubmed:abstractText
Long-acting depot forms of somatostatin analogs administered by intramuscular injections are now available for the treatment of neuroendocrine tumors (NETs). In the present study, we investigated the efficacy and tolerability of a slow-release form of lanreotide in patients with advanced NETs. From July 1996 to January 1999, 25 patients with advanced NETs (12 carcinoids, 13 endocrine pancreatic tumors) were enrolled in the study. Thirteen patients were pretreated with subcutaneous octreotide, chemotherapy, or hepatic metastasis alcoholization. All the patients had measurable disease. Seventeen patients were symptomatic and 20 patients had elevated serum and/or urine markers. Octreotide scintigraphy was positive in 23 of 25 patients. Lanreotide was administered as intramuscular injections at the dose of 30 mg every 2 weeks until there was objective, biochemical, or symptomatic tumor progression. Objective partial responses (PRs) were documented in 2 patients (8%), whereas 10 patients (40%) had tumor stabilization. The PRs were observed in patients with midgut carcinoids, of whom one was pretreated with subcutaneous octreotide. The response duration was 21+ and 24+ months in responding patients; the median duration of disease stabilization was 8.5 months (range, 4-21+). The overall biochemical response rate was 42%, including 2 complete responses (CRs) (10.5%) and 6 PRs (31.5%); all biochemical responses were observed mostly in patients with carcinoid tumors; the duration of response was 18+ and 30+ months for CRs; the median duration of biochemical response was 7 months (range, 4-18+) for PRs. The overall symptomatic response rate was 70% with a median duration of 7.5, 18, and 18+ months for diarrhea, abdominal pain, and flushing, respectively. Median duration of lanreotide treatment was 10 months (range, 2-30+). No significant side effects were reported. Depot lanreotide 30 mg shows significant efficacy in terms of objective response rate and in biochemical and symptomatic control, in pretreated patients as well as nonpretreated patients with advanced NETs. Tolerability is good, with good patient compliance.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
0277-3732
pubmed:author
pubmed:issnType
Print
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
412-5
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed-meshheading:10955874-Abdominal Pain, pubmed-meshheading:10955874-Adult, pubmed-meshheading:10955874-Aged, pubmed-meshheading:10955874-Antineoplastic Agents, pubmed-meshheading:10955874-Carcinoid Tumor, pubmed-meshheading:10955874-Delayed-Action Preparations, pubmed-meshheading:10955874-Diarrhea, pubmed-meshheading:10955874-Disease Progression, pubmed-meshheading:10955874-Female, pubmed-meshheading:10955874-Flushing, pubmed-meshheading:10955874-Gastrinoma, pubmed-meshheading:10955874-Humans, pubmed-meshheading:10955874-Injections, Intramuscular, pubmed-meshheading:10955874-Liver Neoplasms, pubmed-meshheading:10955874-Male, pubmed-meshheading:10955874-Middle Aged, pubmed-meshheading:10955874-Neuroendocrine Tumors, pubmed-meshheading:10955874-Pancreatic Neoplasms, pubmed-meshheading:10955874-Patient Compliance, pubmed-meshheading:10955874-Peptides, Cyclic, pubmed-meshheading:10955874-Remission Induction, pubmed-meshheading:10955874-Somatostatin, pubmed-meshheading:10955874-Tumor Markers, Biological
pubmed:year
2000
pubmed:articleTitle
Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
pubmed:affiliation
Department of Oncology, S. Chiara Hospital and University, Pisa, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Clinical Trial, Phase II